Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986171 in healthy subjects
NCT02538874Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Nov 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of single dose of BMS-986171, Safety and tolerability of multiple subcutaneous doses of BMS-986171 and 2 more. Started Oct 2015; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT02538874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538874.